Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse

S Sale1, R G Tunstall, K C Ruparelia

  • 1Cancer Biomarkers and Prevention Group, Department of Cancer Studies, University of Leicester, Leicester, UK.

Insights

DMU-135, a novel anticancer prodrug, effectively reduced gastrointestinal adenoma formation in mice by 46%. This promising chemopreventive agent shows potential for cancer treatment by targeting tumor-specific enzymes.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Cytochrome P450 enzyme CYP1B1 is selectively expressed in various tumors, including colon cancer.
  • DMU-135 is a novel anticancer prodrug designed for targeted activation by CYP1B1.

Purpose of the Study:

  • To investigate the chemopreventive efficacy of DMU-135 in inhibiting gastrointestinal adenoma formation in Apc(Min/+) mice.

Main Methods:

  • Apc(Min/+) mice were administered DMU-135 (0.2% w:w) in their diet from 4 to 18 weeks of age.
  • Adenoma multiplicity was compared between the treatment group and control group.

Main Results:

  • DMU-135 was well-tolerated and did not induce systemic side-effects.
  • DMU-135 significantly reduced adenoma multiplicity by 46 +/- 18.3% (p < 0.001) compared to controls.

Conclusions:

  • DMU-135 demonstrates significant chemopreventive activity against gastrointestinal adenoma formation.
  • Further characterization of DMU-135 as a promising chemopreventive agent is warranted.